Clinical Trial

A Phase I Study of SNH-119014 in Healthy Volunteers

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 25, 2025 (before its estimated March 28, 2026 completion). Its status may not reflect the trial's current state.
Summary
SNH-119014 is an oral small-molecule agonist of pyruvate kinase red blood cell isozyme (PKR) being developed for the treatment of hemolytic anemias. This initial study will characterize the safety, tolerability and the pharmacokinetics/pharmacodynamics (PK/PD) of a single ascending dose and multiple ascending doses of SNH-119014 in the context of Phase 1 studies in healthy volunteers. The effects of food on the absorption of SNH-119014 will also be evaluated in healthy volunteers.
Trial Details
NCT Number NCT07087262
Lead Sponsor ScinnoHub Pharmaceutical Co., Ltd.
Conditions Hemoglobinopathy
Enrollment 96 participants
Start Date 2025-06-27
Primary Completion 2026-03-28 (estimated)
Study Completion 2026-03-28 (estimated)
Updated on ClinicalTrials.gov 2025-07-25